Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



Search Results - Lorcaserin
 More »

  • Top 20 Best-Selling Drugs Approved and Launched During 2012
    approval: April 25, 2012 Date of FDA approval: December 14, 2012 #17. Belviq® (lorcaserin hydrochloride) 2012 sales: $6 million 3 Marketer(s): Arena Pharmaceuticals and Eisai ...
    4-4-2013
  • Biggest Biotech Trends of 2012
    ... a decade-Vivus' Qsymia (phentermine and topiramate extended-release) and Belviq (lorcaserin hydrochloride), to be made by Arena Pharmaceuticals and distributed by Japan's Eisai. ...
    1-15-2013
  • Getting FDA to Yes
    ... But the agency also okayed the first two weight loss drugs in more than a decade, Vivus' Qsymia (phentermine and topiramate extended-release) and Belviq (lorcaserin hydrochloride), ...
    1-8-2013
  • 7 Biotech Trends for the Coming Year
    ... OBESITY DRUGS: New Drugs Will Shake Up Category The second of two obesity drugs approved last summer will ring up its first sales in 2013-Belviq (lorcaserin hydrochloride), made by ...
    1-3-2013
  • Biggest Biotech Trends of 2012
    ... a decade-Vivus' Qsymia (phentermine and topiramate extended-release) and Belviq (lorcaserin hydrochloride), to be made by Arena Pharmaceuticals and distributed by Japan's Eisai. ...
    12-26-2012
  • Will FDA Bid Adieu to Auld Lang Syne and Open Up to New Drugs...
    Its competitors, Vivus' Qnexa (phentermine + topiramate) and Arena's lorcaserin, were ... of the infamous "Fen-Phen" combo; and lorcaserin is both a new molecular entity and also ...
    9-5-2012
  • Obesity Drug Developers Post Steady Gains
    17. By early 2013, first sales are expected for Belviq (lorcaserin hydrochloride), to be made by Arena Pharmaceuticals and distributed by Japan's Eisai, following June 27 approval. ...
    9-5-2012
  • Obesity Proving Complicated and Personal
    ... In fact, we already have clear signs that obesity is a heterogeneous disease. Lorcaserin, a 5HT2c agonist, produces a more than 3% weight loss when considering all randomized ...
    7-1-2012
  • Arena, Eisai Win FDA Okay for Obesity Drug
    drug Belviq (lorcaserin hydrochloride) for chronic weight management in adults. ... A marketing authorization application for lorcaserin was accepted for filing by the EMA in ...
    6-28-2012
  • Regulatory Environment Warms Up to Obesity Drugs
    could indeed ease the approval path for Arena's lorcaserin and Orexigen's Contrave. ... Arena's lorcaserin unlike Qnexa does not combine existing drugs, a company spokesperson ...
    4-15-2012
  • Regulatory Environment Warms Up to Obesity Drugs and Could Heat...
    could indeed ease the approval path for Arena's lorcaserin and Orexigen's Contrave. ... Arena's lorcaserin unlike Qnexa does not combine existing drugs, a company spokesperson ...
    3-19-2012
  • Orexigen Halts Development of Anti-Obesity Therapies
    ... clinical trial with their candidate, lorcaserin; and Vivus was was asked for clinical, ... And for Arena, they note, "Lorcaserin lowered both heart rate and blood pressure (though ...
    6-3-2011
  • Obesity-Focused Firm Ablaris Adds $1.2M to Series A Financing
    Arena Pharmaceuticals and Eisai were asked to provide additional clinical and nonclinical data as well as conduct another clinical trial with their candidate lorcaserin, a ...
    4-6-2011
  • Arena to Obtain $35.5M in Registered Direct Public Offering
    The decision came after FDA issued the company and its U.S. partner Eisai a complete response letter in relation to its anti-obesity drug, lorcaserin. The agency, which sent the ...
    3-29-2011
  • Amylin and Takeda Halt Phase II Obesity Trial
    ... Arena Pharmaceuticals and Eisai were asked to provide additional clinical and nonclinical data as well as conduct another clinical trial with their candidate lorcaserin, a ...
    3-16-2011

GEN Webinars

View »

GEN Web Briefs

View »

GEN Poll

More » Poll Results » Archive »

Balancing Family and Career for Women Ph.D.s

Which changes made to academic culture are most likely to encourage women researchers to stay?

Suggest a Poll